LumiraDx is a point of care diagnostic company. Co.'s existing test menu includes its International Normalized Ratio test for monitoring warfarin therapy, its Glycated Hemoglobin test for monitoring diabetes, its NT-proBNP test for aiding in the diagnosis of heart failure, its D-Dimer test for aiding in diagnosis and exclusion of venous thromboembolism, and its C-Reactive Protein test which measures a universal biomarker of infection and inflammation. Co. has developed four rapid COVID-19 molecular reagent testing kits for use on open molecular systems, SARS-CoV-2 RNA STAR, SARS-CoV-2 RNA STAR Complete, SARS-CoV-2 & Flu A/B RNA STAR Complete and Dual-Target SARS CoV-2 STAR Complete. We show 1 historical shares outstanding datapoints in our coverage of LMDX's shares outstanding history.
Understanding the changing numbers of LMDX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like LMDX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching LMDX by allowing them to research LMDX shares outstanding history
as well as any other stock in our coverage universe. |
Free LMDX Email Alerts:
Video: Shares Outstanding Importance
